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asthma exacerbations
To the Editor:
Asthma is a common chronic inflammatory disease of the
airways characterized by recurrent episodes of airway inflamma-
tion and following cycles of tissue repair and regeneration.1
Asthma exacerbations are defined as episodes of progressive
increase in shortness of breath, cough, wheezing, and chest
tightness, or a combination of these symptoms, accompanied
by decreases in expiratory airflow that can be quantified by
measurement of lung function.
Factors contributing to exacerbations of asthma symptoms
include respiratory infections (viral, bacterial, and atypical),
allergens (aeroallergens and food allergens), exposures (occupa-
tional allergens and drugs), and miscellaneous factors
(b-adrenergic receptor polymorphisms and nonrespiratory
factors).2 The immune mechanisms underlying acute episodes
of asthma are poorly understood, andwhether factors contributing
to asthma exacerbations for different reasons engage distinct
immune pathways has been studied in the present study.
In patients with asthma, airway inflammation is driven by T
cells, with themost important role attributed to TH2 cells and their
cytokines. There is growing evidence that not only TH2 cells have
been associated with the development and progression of asthma
but also TH17 cells might be involved by supporting the
recruitment and survival of neutrophils, which were detected in
sputum of subjects with asthma exacerbations and severe
persistent asthma.1 Furthermore, data on the function of regulato-
ry T (Treg) cells in asthma in humans are largely incomplete and
quite inconsistent, although their role in allergen tolerance and
allergen-specific immunotherapy has been intensively studied.3
To address these questions in a clinical setting, we used
multicolor flow cytometry for the evaluation of phenotypical
changes in CD41 T cells in subjects with asthma during acute
episodes and stable asthma compared with the control group.
The clinical characteristics of subjects are summarized in Table
E1 in this article’s Online Repository at www.jacionline.org.
Viruses were determined in the induced sputum during
exacerbation. Rhinovirus (n 5 6), metapneumovirus (n 5 1),
parainfluenza-2 virus and metapneumovirus (n 5 1), and
parainfluenza-1 and respiratory syncytial virus (n 5 1) were
identified in 9 virus-induced asthma exacerbation cases.
Our data demonstrate that Treg cells analyzed according to the
gating of CD31CD41 CD251CD1272FOXP31 and Helios1
cells (Fig 1, A) exhibit a major change during asthma exacerba-
tions. Higher numbers of Treg cells in peripheral blood were
found in subjects with stable asthma than in healthy controls. In
contrast, during asthma exacerbations, the number of Treg cells
was significantly reduced than during stable asthma (Fig 1, B).
In addition, the frequency of Treg cells positively correlated
FIG 1. Decreased frequency of Treg cells during asthma exacerbations. A, Treg cells were identified in
CD31CD41 T-cell gate on the basis of the expression of CD25 and CD127 as well as intracellular FOXP3
and Helios. B, The percentage of CD31CD41CD251CD1272 (Treg cells) was significantly decreased in
asthma exacerbations. C, The frequency of Treg cells positively correlates with FEV1%. During asthma
exacerbations, the percentage of FOXP31Helios1 Treg cells was reduced (D) and was positively correlated
with FEV1% (E). HC, Healthy control; no-VEx, nonviral exacerbated asthma; SA, stable asthma; VEx, viral
exacerbated asthma.
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frequency of Treg cells in subjects with stable asthma could be
due to corticosteroid treatment, as previously reported in adult
subjects with asthma.4 The speed of kinetics of decrease and
recovery of Treg cells during asthma exacerbations and
stabilization is difficult to predict without a longitudinal study.The evaluation of migratory properties of Treg cells is limited
by lack of availability of suitable markers for homing to lungs.5
In the present study, we used CCR7 as a marker for migratory
properties of Treg cells toward central lymphatic organs as a
marker for exit from peripheral organs (see Fig E1 in this article’s
Online Repository at www.jacionline.org).5 These data show a
FIG 2. Distinct cytokine profile of CD31CD41 T cells in asthma exacerbations. A, IL-4–producing CD31CD41
T cells. B, IL-10–producing CD31CD41 T cells. C, IL-17A–producing CD31CD41 T cells. D, IL-22–producing
CD31CD41 T cells. E, IFN-g–producing CD31CD41 T cells. HC, Healthy control; no-VEx, nonviral exacerbated
asthma; SA, stable asthma; VEx, viral exacerbated asthma. *P <_ .05, **P <_ .01, and ***P <_ .001.
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with stable asthma than in healthy controls and both exacerbation
groups, whereas during asthma exacerbation reduced frequency
of CCR72 Treg cells was observed probably because of
sequestration of CCR71 cells in the central lymphatic organs.
Conclusive data on a specific recruitment of Treg cells into or
out of the airway tissue requires further studies, which also
enumerate them directly in the lungs.
For the in-depth analysis of Treg cells, forkhead box P3
(FOXP3) and Helios expression on CD251CD1272 Treg cells
was studied. FOXP3 determines the development as well as the
immunosuppressive activity of Treg cells. Helios is a member
of Ikaros family transcription factors, which are involved in the
control of gene transcription through chromatin remodeling.6 In
addition, it was recently demonstrated that these 2 transcription
factors interact and potentiate each other, such as Helios upregu-
lates FOXP3 expression by binding to the promoter of FOXP3.6
According to the expression of FOXP3 and Helios, 4 distinct
subsets of Treg cells were discriminated (see Fig E2, A and B, in
this article’s Online Repository at www.jacionline.org). In healthy
donors and subjects with stable asthma,most of theTreg cells were
FOXP31Helios1. In contrast, during acute asthma episodes,decreased frequency of Treg cells with both FOXP31Helios1
expression was observed than in subjects with stable asthma and
the control group (Fig 1,D). As observed inCD41CD251CD1272
Treg cells, the frequency of Treg cells expressing both FOXP3 and
Helios positively correlated with FEV1% (Fig 1, E).
The pattern of single or coexpression of FOXP3 and Helios by
Treg cells showed interesting insights into the expression of these
transcription factors on Treg cells (Fig E2). During asthma
exacerbations, the frequency of Treg cells expressing both
transcription factors was reduced. In addition, the expression of
both FOXP3 and Helios positively correlated with FEV1%
because of a very high correlation of these 2 transcription factors
with each other (see Fig E3, A and B, in this article’s Online
Repository at www.jacionline.org). Interestingly, Treg cells
with the phenotype of CD41CD251CD1272, which are
FOXP31, but Helios2 as well as both FOXP32 and Helios2 cells
have expanded in acute asthma episodes, and both subsets showed
a negative correlation with FEV1%.
To further characterize theCD31CD41Tcells, the production of
TH cell lineage-specific prototype cytokines IL-4, IL-10, IL-17A,
IL-22, and IFN-gwas evaluated (Fig2; seeFigE4,A, in this article’s
Online Repository at www.jacionline.org). The data demonstrated
J ALLERGY CLIN IMMUNOL
VOLUME 136, NUMBER 1
LETTERS TO THE EDITOR 197distinct cytokine expression patterns between viral and nonviral
asthma exacerbations. Asthma exacerbations triggered by a
nonviral factor, most commonly an allergen, were characterized
with increased frequency of IL-4–producing CD31CD41 T cells
(Fig 2, A); however, the frequency of that population did not
correlate with FEV1% (see Fig E5, A, in this article’s Online
Repository at www.jacionline.org). IL-4 in combination with other
TH2-related cytokines, such as IL-5 and IL-13, are involved in the
development of pathophysiological features of asthma and allergic
inflammation.1,7 In addition, increased numbers of IL-10–
producingCD31CD41Tcellswere detected in thosewith nonvirus
asthma exacerbations than in healthy controls and subjects with sta-
ble asthma (Fig2,B). Interestingly, a negative correlationwas found
between IL-102producing CD31CD41 T cells and FEV1% (Fig
E5,B). IL-17A expression inCD41T cells represented a peripheral
marker of asthma exacerbation. Both viral and nonviral acute
asthma episodes were strongly associated with increased percent-
age of IL-17A–producing CD31CD41 T cells (Fig 2, C), which
showed a negative correlation with FEV1% (Fig E5,C). IL-17A in-
duces the production of proinflammatory cytokines and
chemokines by airway epithelial cells, fibroblasts, and other cell
types, which plays a role in the influx of neutrophils and macro-
phages to the site of inflammation, and their excessive activation
leading to tissue damage.1,7,8 The induction of IL-22–producing
CD31CD41 T cells was also identified in asthma exacerbations
triggered by a nonviral factor (Fig 2, D), without showing any cor-
relation with FEV1% (Fig E5, D). The percentage of IFN-
g–producing T cells was similar in all groups (Fig E5, E) and did
not correlate with FEV1% (Fig E5, E).
In addition to single cytokine expression, our data demonstrate
increased frequency of CD41 T cells with a coexpression
phenotype of IL-17A1IL-101, IL-41IL-101, IL-41IL-17A1,
IL-41IL-221, IL-17A1IL-221, and IL-221IL-101 in nonviral
asthma exacerbations, suggesting a general activation of effector
cytokines in CD41 T cells (see Fig E6 in this article’s Online
Repository at www.jacionline.org). In contrast to IL-17A, IL-22
exhibits proinflammatory, anti-inflammatory properties as well
as tissue regenerative features.7,8 It might be assumed that the
simultaneous production of IL-22 and IL-17A is responsible for
overcoming the tissue damage resulting from the ongoing inflam-
matory process. IL-22 is an IL-10 family cytokine member and
plays an important role inmucosal immunity. The role of IL-222-
producing T cells in bronchial asthma in humans is unknown.8
Interestingly, increased levels of IL-22 in the serum of subjects
with asthma have been reported.8 Furthermore, studies in animal
models have demonstrated an involvement of IL-22 in regulation
of the infiltration of eosinophils to the airways.9 In addition, it may
be involved in the stabilization of lung epithelial integrity and ho-
meostasis. However, further studies are required to clarify the role
of TH22 cells in asthma and their exacerbations. Individuals
treated with systemic corticosteroids showed heterogeneity in
the populations of effector and regulatory T-cell subsets in the pe-
riphery, and it requires further studies for in-depth analyses (see
Fig E7 in this article’s Online Repository at www.jacionline.org).
In conclusion, our data demonstrate that multicolor flow
cytometry represents a relatively rapid tool to investigate
peripheral blood lineage-specific CD41 T-cell characterization
that may open a new window for the identification of the etiology
of asthma exacerbations. Distinct immune activation and immune
regulation pathways were demonstrated in exacerbations due to
viral or nonviral etiology. Longitudinal studies are required forbetter understanding of immune response associated with asthma
exacerbations. The knowledge of the dynamics of changes in
peripheral blood T cells may allow the development of rapid tests
for cellular diagnosis of asthma exacerbations.
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Prevention of allergic asthma through Der p 2
peptide vaccination
To the Editor:
House dust mites (HDMs) are a major source of allergens
that affect more than 50% of allergic patients.1-3 The
METHODS
Subjects
The study population consisted of 38 asthmatic patients diagnosed
according to the Global Initiative for Asthma 2012 update. They were
consecutively recruited from the outpatient’s clinics at the Department of
Pulmonary Disease, University Hospital, Krakow. The clinical characteristics
of the study patients are presented in Table E1. The study participants were
stratified into a stable asthma group (n5 21) if none had experienced an exac-
erbation or a respiratory tract infection within the 6-week period preceding the
study and their baseline FEV1wasmore than 70%of the predicted value on the
visit day. Asthma exacerbation was defined according to the joint American
Thoracic Society/European Respiratory Society statement on Asthma Control
and Exacerbations,E1 and the study subjects (n 5 16) were recruited during
their unscheduled or emergency visits and before their treatment modification.
Asthmatic patients enrolled into exacerbation groups were complaining of
shortness of breath, cough for at least 2 days, and a little or no improvement
in symptoms was observed after rescue medication with beta-agonist. The
severity grade of asthma exacerbation was classified as moderate, and there
was no significant difference between viral and nonviral exacerbations in
retrospective analysis after the screening of viruses was completed. None of
the patients was treated with leukotriene-modifying drugs at the time of blood
sampling. Only 4 subjects among the asthmatic group were treated with sys-
temic glucocorticoids (Table E1). There was no significant effect of treatment
with glucocorticoids on the frequencies of respective T-cell subsets analyzed
in the present study (Fig E7). Subjects with asthma exacerbations were
routinely screened for viral pathogens using nasal lavage samples. Themethod
was based on PCR as published elsewhere.E2 This screening revealed the pres-
ence of respiratory viral pathogens in 9 of the asthmatic patients (Table E1).
The patients gave informed consent to participate in the study, and official
approval from the Jagiellonian University Ethics Committee was obtained
(KBET/7/B/2010). Healthy volunteers were recruited for the control group
from among the staff of the Swiss Institute for Allergy and Asthma Research.
None of the control subjects had any allergic disorders or were taking any
medications.
PBMCs—Isolation and culture conditions
Human PBMCs were separated from peripheral venous blood of asthmatic
individuals and healthy volunteers using Ficoll-Hypaque (Sigma, St Louis,
Mo) density-gradient centrifugation. PBMCs were cryopreserved and stored
in liquid nitrogen until use. Cells were thawed and incubated at a density of 1
3 106 per mL in 24-well plates at 378C and 5% CO2 for 1.5 hours in RPMI
1640 supplemented with 2 mM L-glutamine, 1% (v/v) nonessential amino
acids and minimum essential medium vitamins solution, 1 mM sodium
pyruvate, 100 U/mL penicillin, 100 mg/mL streptomycin, 50 mg/mL
kanamycin, 50 mM b-mercaptoethanol (all from Invitrogen, Basel,
Switzerland), and 10% (v/v) heat-inactivated FCS (Sigma). For intracellular
cytokine determination, PBMCs were activated with 20 ng/mL PMA and 1
mg/mL ionomycin for 4 hours in the presence of 10 mg/mL brefeldin
A (all from Sigma).
Staining and flow-cytometry analysis
PBMCs with or without stimulation were washed with PBS and stained
with Fixable Viability Dye eFluor780 (VDeF780; eBioscience, San Diego,
Calif) to exclude nonviable cells. Cells were surface stained at 48C in the dark
for 30minutes, and then fixed and permeabilized by FoxP3 Fix/Perm buffer set
(Biolegend, San Diego, Calif) or Cytofix/Cytoperm kit (BD, San Diego, Calif)
according to the manufacturer’s protocol. Antibodies used for surface and
intracellular staining included anti-CD3 (UCHT1; BD Horizon, San Diego,
Calif), anti-CD4 (RPA-T4; Biolegend), anti-CD4 (T4; Beckman Coulter,
Fullerton, Calif), anti-CD25 (BC96; Biolegend), anti-CD127 (IM19800U;
Beckman Coulter), anti-CD197 (3D12; BD Pharmingen, San Diego, Calif),
anti-FOXP3 (259D; Biolegend), anti-Helios (22F6; Biolegend), anti–IL-4
(8D4-8; BD Pharmingen), anti–IL-10 (JES3-9D7; Biolegend), anti–IL-17A
(BL168; Biolegend), anti–IL-22 (22URTI; eBioscience), and anti–IFN-g
(4S.B3; Biolegend), all conjugated with separate fluorochromes. Appropriate
isotype controls were used to determine specific staining.
All data were acquired on Galios Flow Cytometer (Beckman Coulter), and
their analysis was performed by using Kaluza Analysis Software (Beckman
Coulter).
Statistical analysis
The Kruskall-Wallis test followed by Dunn post hoc test of multiple
comparison and nonparametric correlation (Spearman) were used for
statistical analysis, and a statistical error type I P value of less than .05 was
considered significant. All statistical analysis was performed with GraphPad
Prism software (GraphPad Software, Inc, La Jolla, Calif).
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FIG E1. Subjects with asthma exacerbations show decreased frequencies of CCR71/2 Treg cells than do
subjects in the stable asthma group. A, Representative dot plots for classification of Treg cells according
to expression of CCR7. The CD31CD41 population was distinguished between CCR71 and CCR72 subsets
and subsequently in each of these populations, Treg cells were identified on the basis of the expression
of CD25 and CD127. The frequencies of CD251CD1272CCR71/2 were presented as a percentage of the
CD31CD41 population. B, Increased frequency of CCR71 Treg cells in subjects with stable asthma.
C, Subjects with asthma exacerbations exhibit decreased frequency of CCR72 Treg cells than do subjects
in the healthy control group and subjects with stable asthma. Differences with P < .05 were considered
statistically significant. HC, Healthy control; SA, stable asthma; no-VEx, nonviral exacerbated asthma;
VEx, viral exacerbated asthma. *P <_ .05, **P <_ .01, and ***P <_ .001.
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FIG E2. Changes in the expression of transcription factors FOXP3 and Helios in Treg cells during asthma
exacerbations. A, According to the expression of FOXP3 and Helios, Treg cells were divided into 4 distinct
subsets (FOXP32Helios2, FOXP31Helios2, FOXP31Helios1, and FOXP32Helios1). Treg cells positive for
FOXP3 (FOXP31) were a combination of FOXP31Helios2 and FOXP31Helios1 populations. Treg cells
positive for Helios (Helios1) consisted of FOXP32Helios1 and FOXP31Helios1 cells. B,Most of the Treg cells
in healthy controls and in subjects with stable asthma were FOXP31Helios1, whereas during asthma
exacerbations a reduction in the number of FOXP31Helios1 and an increased frequency of FOXP31Helios2
and FOXP32Helios2 Treg cells were observed. The percentage of FOXP31 Treg cells was reduced in asthma
exacerbations (C) and was positively correlated with FEV1% (D). The frequency of Helios1 Treg cells was
decreased in asthma exacerbations (E) and was positively correlated with FEV1% (F). Asthma exacerbations
were characterized by increased frequency of FOXP31Helios2 Treg cells (G), which negatively correlated
with FEV1% (H). Increased frequency of Treg cells negative for both FOXP3 and Helios was observed in
asthma exacerbations (I) and was negatively correlated with FEV1% (J). Differences of P < .05 were
considered statistically significant. HC, Healthy control; SA, stable asthma; no-VEx, nonviral exacerbated
asthma; VEx, viral exacerbated asthma. *P <_ .05, **P <_ .01, and ***P <_ .001.
=
FIG E3. Correlation between the expressions of FOXP3 and Helios in Treg cells. The expression of FOXP3
was highly correlated with the expression of Helios both in subjects with stable asthma and healthy controls
(A) and in subjects with asthma exacerbations (B).
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FIG E4. Flow-cytometric evaluation of the production of IL-4, IL-10, IL-17A, IL-22, and IFN-g by peripheral
blood CD31CD41 T cells. PBMCs were stimulated with PMA and ionomycin in the presence of
brefeldin A, and the cytokine expression was analyzed by intracellular staining of CD31CD41 T cells.
A, The representative dot plots for cytokine–producing CD31CD41 T cells are presented. PMA, Phorbol
12-myristate 13-acetate.
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FIG E5. The frequency of IL-17A2producing cells negatively correlates with FEV1%. The correlation
between cytokine-producing CD31CD41 T cells and FEV1%was determined. A, There was no correlation be-
tween IL-4–producing CD31CD41 T cells and FEV1%. B, The percentage of IL-10–producing CD3
1CD41
T cells was negatively correlated with FEV1%. C, Negative correlation to FEV1% was shown by
IL-17A–producing CD31CD41 T cells. No correlation between FEV1% and the percentages of
IL-22–producing (D) and between FEV1% and the percentages of IFN-g–producing CD3
1CD41 T cells
(E) was observed.
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FIG E6. The cytokine profile of CD31CD41 T cells. IFN-g–producing CD31CD41 T cells were able to
coproduce IL-17A (A), IL-4 (B), IL-22 (C), and IL-10 (D). IL-17A–producing CD31CD41 T cells coexpress IL-4
(E), IL-22 (F), and IL-10 (G). IL-4–producing CD31CD41 T cells were able to coexpress IL-22 (H) and IL-10
(I). J, IL-22 and IL-10–producing CD31CD41 T cells were detected. HC, Healthy control; SA, stable asthma;
no-VEx, nonviral exacerbated asthma; VEx, viral exacerbated asthma. *P <_ .05, **P <_ .01, and ***P <_ .001.
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FIG E7. The impact of systemic glucocorticoid (GC) treatment on Treg
cells and the cytokine profile of T cells. Subjects treated with systemic GCs
(n 5 4) were analyzed separately and compared with other asthmatic
groups. Two of them were among stable asthma subjects and the other 2
among subjects with exacerbated asthma (viral exacerbated asthma, n5 1,
and nonviral exacerbated asthma, n 5 1). A, The prevalence of T cells
producing IL-4, IL-10, IL-22, and IFN-g in subjects treated with GCs did not
differ from the control group and subjects with stable asthma. Subjects
treated with systemic GCs have shown a tendency to increased frequency
of CD31CD41IL-17A1 T cells. B, Subjects treated with GCs showed
heterogeneity for Treg-cell populations. Subjects treated with systemic
GCs showed diversity with 2 low and 2 high expressions of FOXP3 and
Helios. The reasons for this remain to be further analyzed. There was no
difference between the control group and subjects with stable asthma as
well as those with asthma exacerbations in analyzed parameters.
HC, Healthy control; SA, stable asthma; no-VEx, nonviral exacerbated
asthma; VEx, viral exacerbated asthma.
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TABLE E1. Characteristics of study subjects
Characteristic Stable asthma Viral exacerbated asthma* Nonviral exacerbated asthma Healthy controls
n 21 9 7 13
Sex: male/female 5/16 4/5 3/4 7/6
Age (y), mean 6 SD 44.77 6 13.75 40.56 6 13.57 59.57 6 7.76 45 6 13.53
Duration of asthma (y), mean 6 SD 12.82 6 14.57 10.44 6 8.47 14.29 6 15.63 NA
Total serum IgE (kU/dL), median (IQR) 67.0 (24.0-191) 71 (35-298) 411 (203-598) NA
Peripheral blood eosinophilia
(cells per mm3), median (IQR)
364 (140-518) 240 (82-502) 426 (199-630) NA
FEV1% 91.55 6 11.10 74.31 6 8.45 75.68 6 8.38 NA
Hypersensitivity to nonsteroidal
anti-inflammatory drugs, %
59.1 66.7 42.9 NA
Chronic rhinosinusitis, % 95.5 88.9 57.1 0
Positive skin test results with common
allergens, %
40.1 33.3 71 NA
GINA asthma severity, median (IQR) 2 (1-3) 2 (1-3) 4 (2-4) NA
Oral corticosteroids (%, average dose mg) 9.0, 16 11.1, 8 14.3, 4 0%
Inhalatory corticosteroids (%, average
dose mg, [range])
86.4, 500 (200-1000) 88.9, 960 (560-1000) 100, 1000 (500-1800) 0%
Asthma control test, median (IQR) 21 (17-25) 23 (16-25) 17 (8-21) NA
Oral corticosteroids recalculated for methylprednisolone equivalent; inhaled corticosteroids recalculated for fluticasone equivalent.
IQR, Interquartile range; FEV1%, predicted percentage of FEV1; GINA, Global Initiative for Asthma; NA, not applicable/available.
*Viruses detected in the induced sputum during exacerbation were human: rhinovirus (n 5 6), metapneumovirus (n 5 1), parainfluenza-2 virus and metapneumovirus (n 5 1), and
parainfluenza-1 and respiratory syncytial (n 5 1), as described in Pyrc et al.E2
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